KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Equity Income: 2018-2024

Historic Equity Income for Royalty Pharma (RPRX) over the last 7 years, with Dec 2024 value amounting to $39.5 million.

  • Royalty Pharma's Equity Income fell 62.90% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.5 million, marking a year-over-year decrease of 172.82%. This contributed to the annual value of $39.5 million for FY2024, which is 54.61% down from last year.
  • As of FY2024, Royalty Pharma's Equity Income stood at $39.5 million, which was down 54.61% from $87.1 million recorded in FY2023.
  • Royalty Pharma's 5-year Equity Income high stood at $247.1 million for FY2020, and its period low was -$48.1 million during FY2021.
  • Its 3-year average for Equity Income is $31.1 million, with a median of $39.5 million in 2024.
  • Per our database at Business Quant, Royalty Pharma's Equity Income plummeted by 119.45% in 2021 and then spiked by 360.57% in 2023.
  • Yearly analysis of 5 years shows Royalty Pharma's Equity Income stood at $247.1 million in 2020, then plummeted by 119.45% to -$48.1 million in 2021, then surged by 30.42% to -$33.4 million in 2022, then spiked by 360.57% to $87.1 million in 2023, then crashed by 54.61% to $39.5 million in 2024.